Asunto(s)
Neoplasias Esofágicas/diagnóstico , Esofagitis/diagnóstico , Tuberculosis Gastrointestinal/diagnóstico , Anciano , Antituberculosos/uso terapéutico , Trastornos de Deglución/etiología , Diagnóstico Tardío , Diagnóstico Diferencial , Terapia por Observación Directa , Endoscopía del Sistema Digestivo , Esofagitis/tratamiento farmacológico , Esofagitis/patología , Etambutol/uso terapéutico , Fiebre/etiología , Humanos , Isoniazida/uso terapéutico , Ganglios Linfáticos/diagnóstico por imagen , Ganglios Linfáticos/patología , Linfadenopatía/diagnóstico por imagen , Linfadenopatía/patología , Masculino , Americanos Mexicanos , Pirazinamida/uso terapéutico , Rifampin/uso terapéutico , Trastornos Relacionados con Sustancias/complicaciones , Tomografía Computarizada por Rayos X , Tuberculosis Gastrointestinal/complicaciones , Tuberculosis Gastrointestinal/tratamiento farmacológico , Tuberculosis Gastrointestinal/patología , UltrasonografíaRESUMEN
Background: A key component to monitoring and investigating patient QOL is through patient reported health related quality of life (HRQOL) outcome measures. Many instruments have been used to assess HRQOL in bladder cancer and each instrument varies in its development, validation, the context of its usage in the literature and its applicability to certain disease states. Objective: In this review, we sought to summarize how clinicians and researchers should most appropriately utilize the available HRQOL instruments for bladder cancer. Methods: We performed a comprehensive literature search of each instrument used in bladder cancer, paying particular attention to the outcomes assessed. We used these outcomes to group the available instruments into categories best reflecting their optimal usage by stage of disease. Results: We found 5 instruments specific to bladder cancer, of which 3 are validated. Only one of the instruments (the EORTC-QLQ-NMIBC24) was involved in a randomized, prospective validation study. The most heavily used instruments are the EORTC-QLQ-BLM30 for muscle-invasive disease and the FACT-Bl which is used across all disease states. Of the 5 available instruments, 4 are automatically administered with general instruments, while the BCI lacks modularity, and requires co-administration with a generalized instrument. Conclusion: There are multiple strong instruments for use in gauging HRQOL in bladder cancer patients. We have divided these instruments into three categories which optimize their usage: instruments for use following NMIBC treatments (EORTC-QLQ-NMIBC24), instruments for use following radical cystectomy (FACT-Bl-Cys and EORTC-QLQ-BLM30) and more inclusive instruments not limited by treatment modality (BCI and FACT-Bl).
RESUMEN
Radical cystectomy (RC) is a complex procedure that can involve long postoperative hospital stays and complicated, burdensome recoveries. Enhanced recovery after surgery is a broad term encompassing an overall approach to perioperative management of postsurgical patients and is becoming more widely accepted for cystectomy patients. This review examines the current evidence for using enhanced recovery protocols for RC as well as current rates of adoption of enhanced recovery among urologists performing RC. We also discuss the next steps for overcoming barriers to the widespread implementation of enhanced recovery for RC.